文献速递脑血管病

ATACH-2与MISTIE III试验中脑微出血与急性血肿特征的关系

Cerebral Microbleeds and Acute Hematoma Characteristics in the ATACH-2 and MISTIE III Trials.
PubMed 文献 · Neurology · 2021-12-22

本研究汇总ATACH-2和MISTIE III两项试验中466例脑出血患者的个体数据,其中231例(49.6%)存在脑微出血。调整混杂因素后,脑微出血与较小的入院血肿体积(β=-0.26,95%CI -0.44至-0.08)及较低的血肿扩大风险(OR 0.65,95%CI 0.40-0.95;P=0.04)相关。

要点

  • 脑微出血与入院时血肿体积较小相关(β=-0.26,95%CI -0.44至-0.08)。
  • 脑微出血与血肿扩大风险降低相关(OR 0.65,95%CI 0.40-0.95;P=0.04)。
  • 脑微出血数量增多时,其与血肿特征的关联强度增加。

核心结论

  • 在脑出血患者汇总队列中,结果与以下假设一致:以小血管病(以脑微出血为代表)更严重者,基线血肿体积较小且血肿扩大减少。

研究设计与样本

  • 汇总ATACH-2试验与MISTIE III试验的个体患者数据,纳入具有脑MRI扫描的脑出血患者。
  • 母试验共纳入1499例脑出血患者,本分析纳入466例(31.1%),其中231例(49.6%)存在脑微出血。
  • 暴露为脑微出血的存在,共同主要结局为入院时脑出血体积和血肿扩大。
  • 采用混合效应线性与逻辑回归模型,人口学与合并症作为固定效应,研究队列作为随机效应。

主要发现

  • 在调整模型中,脑微出血的存在与较小的脑出血体积相关(β=-0.26,95%CI -0.44至-0.08)。
  • 在调整模型中,脑微出血的存在与较低的血肿扩大风险相关(OR 0.65,95%CI 0.40-0.95;P=0.04)。
  • 脑微出血与血肿特征的关联强度随脑微出血数量增加而增加。
  • 脑微出血的部位及脑白质疏松的严重程度未改变上述结果。

关键数值与推荐

  • 本研究提供Class II证据:MRI上微出血的存在与入院时较小的脑出血体积及随访影像中较低的血肿扩大率相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To study the relationship between the presence of cerebral microbleeds (CMBs) and acute hematoma characteristics among patients with primary intracerebral hemorrhage (ICH). METHODS: We pooled individual patient data from the Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) trial and the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation phase 3 (MISTIE III) trial. We included individuals with a brain MRI scan. Exposure was the presence of a CMB. The coprimary outcomes were admission ICH volume and hematoma expansion. Mixed-effects linear and logistic regression models were used, with demographics and comorbid conditions considered fixed effects and the study cohort treated as a random effect. Additional analyses assessed the relationship between CMB topography and number and hematoma characteristics. RESULTS: Of the 1,499 patients with ICH enrolled in the parent trials, 466 (31.1%) were included in this analysis, and 231 (49.6%) patients had CMBs. In adjusted models, presence of CMBs was associated with smaller ICH volume (β = -0.26, 95% confidence interval [CI] -0.44 to -0.08) and lower odds of hematoma expansion (odds ratio 0.65, 95% CI 0.40-0.95; p = 0.04). The strength of association between CMBs and hematoma characteristics increased with increasing number of CMBs. The location of the CMBs and the severity of leukoaraiosis did not modify these results. DISCUSSION: In a pooled cohort of patients with ICH, our results are consistent with the hypothesis that more severe underlying small vessel disease, as represented by CMBs, leads to smaller baseline hematoma volumes and reduced hematoma expansion. Underlying cerebral small vessel disease may be of prognostic significance after ICH. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT01176565 and NCT01827046. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the presence of microbleeds on MRI is associated with a smaller ICH volume at presentation and a lower rate of hematoma expansion on follow-up imaging.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Magid-Bernstein JR, Li Y, Cho SM, et al. Cerebral Microbleeds and Acute Hematoma Characteristics in the ATACH-2 and MISTIE III Trials. Neurology. 2021. PMID: 34937780. doi:10.1212/WNL.0000000000013247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。